Profile data is unavailable for this security.
About the company
Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing differentiated and novel therapies to address the unmet medical needs of patients with cancer. It has a next generation bioconjugation platform, called VersAptx. The VersAptx platform is a versatile and adaptable, next generation bioconjugation platform. Its product candidates include VIP943 (CD123-KSPi), VIP924 (CXCR5-KSPi), VIP236, and Enitociclib (P-TEFb/CDK9 inhibitor). VIP943 is a potential anti-CD123 ADC created with its VersAptx Platform. It consists of an anti-CD123 antibody, a novel legumain-cleavable linker, and a KSPi payload enhanced with its CellTrapper technology. Enitociclib is a selective CDK9 inhibitor. Enitociclib effectively blocks P-TEFb-mediated activation of RNA polymerase II, preventing transcription of MCL1 and MYC, proteins associated with poor prognosis in various types of cancer.
- Revenue in USD (TTM)0.00
- Net income in USD-28.90m
- Incorporated2018
- Employees42.00
- LocationVincerx Pharma Inc260 Sheridan Avenue, Suite 400PALO ALTO 94306United StatesUSA
- Phone+1 (650) 800-6676
- Fax+1 (302) 655-5049
- Websitehttps://vincerx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bullfrog AI Holdings, Inc. | 65.00k | -6.08m | 18.29m | 4.00 | -- | 3.40 | -- | 281.41 | -0.8441 | -0.8441 | 0.009 | 0.6860 | 0.0107 | -- | -- | 16,250.00 | -100.10 | -- | -117.94 | -- | 92.00 | -- | -9,331.34 | -- | -- | -328.51 | 0.0596 | -- | 550.00 | -- | -91.11 | -- | -- | -- |
| Biomx Inc | 0.00 | -26.25m | 18.36m | 58.00 | -- | -- | -- | -- | -0.4575 | -0.4575 | 0.00 | 0.3929 | 0.00 | -- | -- | 0.00 | -47.79 | -- | -57.76 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.59 | -- | -- | -- |
| Finch Therapeutics Group Inc | 0.00 | -14.17m | 18.40m | 18.00 | -- | 1.29 | -- | -- | -8.82 | -8.82 | 0.00 | 8.86 | 0.00 | -- | -- | -- | -25.20 | -- | -28.80 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -87.57 | -- | 34.80 | -- | -- | -- |
| Spruce Biosciences Inc | 9.57m | -43.11m | 18.49m | 22.00 | -- | 0.3124 | -- | 1.93 | -1.05 | -1.05 | 0.2338 | 1.43 | 0.095 | -- | -- | 330,069.00 | -42.79 | -41.24 | -52.43 | -46.49 | -- | -- | -450.38 | -1,774.39 | -- | -117.26 | 0.0412 | -- | -- | -- | -3.77 | -- | -- | -- |
| Brainstorm Cell Therapeutics Inc | 0.00 | -12.75m | 18.98m | 29.00 | -- | -- | -- | -- | -0.2242 | -0.2242 | 0.00 | -0.0443 | 0.00 | -- | -- | 0.00 | -223.03 | -117.19 | -- | -231.65 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 29.18 | -- | -45.34 | -- |
| NanoViricides Inc | 0.00 | -9.51m | 19.61m | 7.00 | -- | 1.84 | -- | -- | -0.8115 | -0.8115 | 0.00 | 0.9017 | 0.00 | -- | -- | 0.00 | -63.30 | -43.54 | -65.85 | -46.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.94 | -- | -8.90 | -- |
| Nymox Pharmaceutical Corp | 0.00 | -8.84m | 19.64m | 3.00 | -- | -- | -- | -- | -0.0966 | -0.0966 | 0.00 | -0.0339 | 0.00 | -- | -- | -- | -785.44 | -306.39 | -- | -749.37 | -- | -- | -- | -43,683.47 | -- | -157.57 | -- | -- | -- | -- | -34.49 | -- | -39.16 | -- |
| Goldenwell Biotech Inc | 940.00 | -137.11k | 19.80m | -- | -- | 5,169.71 | -- | 21,063.83 | -0.0014 | -0.0014 | 0.00001 | 0.00004 | 0.0048 | 0.0031 | -- | -- | -69.82 | -- | -70.29 | -- | 42.55 | -- | -14,586.17 | -- | 21.43 | -- | 0.00 | -- | -95.10 | -- | 88.13 | -- | -- | -- |
| Minerva Neurosciences Inc | 0.00 | -33.65m | 19.93m | 9.00 | -- | -- | -- | -- | -4.44 | -4.44 | 0.00 | -6.36 | 0.00 | -- | -- | 0.00 | -59.32 | -49.89 | -62.70 | -52.39 | -- | -- | -- | -442.65 | -- | -- | -- | -- | -- | -- | 6.55 | -- | -- | -- |
| MEI Pharma Inc | 66.75m | 26.16m | 20.26m | 46.00 | 0.7744 | 0.3969 | 0.764 | 0.3034 | 3.93 | 3.93 | 10.02 | 7.66 | 0.6498 | -- | 29.15 | 1,451,174.00 | 25.46 | -25.31 | 30.38 | -28.59 | -- | -- | 39.18 | -122.05 | -- | -- | 0.00 | -- | 19.95 | 97.56 | 41.53 | -- | -- | -- |
| Vincerx Pharma Inc | 0.00 | -28.90m | 20.41m | 42.00 | -- | 1.32 | -- | -- | -1.31 | -1.31 | 0.00 | 0.5206 | 0.00 | -- | -- | 0.00 | -101.76 | -- | -136.61 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 36.24 | -- | -- | -- |
| Pieris Pharmaceuticals Inc | 20.87m | -23.82m | 21.34m | 46.00 | -- | 1.14 | -- | 1.02 | -19.12 | -19.12 | 16.67 | 14.17 | 0.3707 | -- | 17.13 | 453,739.10 | -42.31 | -28.41 | -66.27 | -39.69 | -- | -- | -114.11 | -94.61 | -- | -- | 0.00 | -- | 65.28 | 8.03 | 26.25 | -- | -36.82 | -- |
| Palatin Technologies, Inc. | 5.90m | -32.20m | 21.95m | 34.00 | -- | 13.90 | -- | 3.72 | -2.39 | -2.39 | 0.4275 | 0.0979 | 0.3189 | 0.6402 | 6.95 | 173,588.80 | -173.98 | -26.11 | -387.23 | -30.68 | 96.58 | -- | -545.58 | -126.20 | 1.20 | -- | 0.0443 | -- | 230.53 | -40.87 | 23.91 | -- | 80.82 | -- |
| Geovax Labs Inc | 300.68k | -26.92m | 22.56m | 17.00 | -- | -- | -- | 75.03 | -13.05 | -13.05 | 0.1389 | -0.5526 | 0.0237 | -- | -- | 17,687.06 | -212.40 | -108.34 | -362.39 | -147.24 | -- | -- | -8,951.51 | -1,842.93 | -- | -- | -- | -- | -100.00 | -- | -85.20 | -- | -- | -- |
| Hcw Biologics Inc | 3.92m | -38.37m | 22.69m | 45.00 | -- | -- | -- | 5.78 | -1.04 | -1.04 | 0.1068 | -0.1666 | 0.1183 | -- | 5.76 | 87,170.22 | -115.73 | -- | -199.07 | -- | 31.17 | -- | -978.10 | -- | -- | -146.50 | 2.75 | -- | -57.72 | -- | -67.74 | -- | -- | -- |
Data as of Sep 19 2024. Currency figures normalised to Vincerx Pharma Inc's reporting currency: US Dollar USD
32.50%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Prosight Management LPas of 30 Jun 2024 | 2.49m | 8.06% |
| Armistice Capital LLCas of 30 Jun 2024 | 1.99m | 6.44% |
| Sage Rhino Capital LLCas of 30 Jun 2024 | 1.70m | 5.52% |
| Rock Springs Capital Management LPas of 30 Jun 2024 | 891.72k | 2.89% |
| Point72 Asset Management LPas of 30 Jun 2024 | 674.19k | 2.18% |
| Goldman Sachs & Co. LLC (Private Banking)as of 30 Jun 2024 | 631.42k | 2.05% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 621.49k | 2.01% |
| ExodusPoint Capital Management LPas of 30 Jun 2024 | 477.95k | 1.55% |
| Marshall Wace LLPas of 30 Jun 2024 | 328.53k | 1.06% |
| Geode Capital Management LLCas of 30 Jun 2024 | 230.79k | 0.75% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
